{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:55:00Z","timestamp":1794272100486,"version":"4.9.0"},"reference-count":302,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005317","name":"Kermanshah University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disease with severe movement problems. Current treatments mainly focus on symptom management by reducing dopaminergic pathways in the brain. Despite these therapies, ongoing disease progression undermines the effectiveness of prevalent approaches, necessitating exploring alternative methods anchored on genetic factors, notably the leucine-rich repeat kinase 2 (LRRK2) gene. Exploring LRRK2 gene pathogenesis has highlighted various mechanisms that may contribute to treating PD, including protein accumulation, altered cytoskeletal dynamics, neuro-inflammation, autophagy, and mitochondrial dysfunction. Based on the findings, there is an actual correlation between elevated levels of LRRK2 and the biomarkers and assays of PD. Furthermore, research results have suggested inhibiting LRRK2 as a therapeutic intervention targeting pathogenic mechanisms with varying degrees of efficacy. Our review wants to understand how LRRK2 works in the body and its relationship with the occurrence of PD by providing biochemical evidence, LRRK2 gene mutations and pathology, and the role of this gene in the immune system. We also discuss targeted therapies such as kinase inhibitors and Proteolysis targeting chimera and the application of using the LRRK2 protein to diagnose PD and develop bioassay designs. Finally, we mention the clinical trials conducted and the challenges and safety required.<\/jats:p>","DOI":"10.1186\/s12967-025-06354-0","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:05:40Z","timestamp":1751954740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Recent advances in targeting LRRK2 for Parkinson\u2019s disease treatment"],"prefix":"10.1186","volume":"23","author":[{"given":"Mahsa","family":"Karami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantea Majma","family":"Sanaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atousa","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshanak","family":"Amirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Goleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehregan","family":"Babamohamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-5202","authenticated-orcid":false,"given":"Zhila","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"12","key":"6354_CR1","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.3390\/cells9122565","volume":"9","author":"GR Jeong","year":"2020","unstructured":"Jeong GR, Lee BD. Pathological functions of LRRK2 in Parkinson\u2019s disease. Cells. 2020;9(12):2565.","journal-title":"Cells"},{"issue":"1","key":"6354_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00207454.2018.1486837","volume":"129","author":"AU Khan","year":"2019","unstructured":"Khan AU, Akram M, Daniyal M, Zainab R. Awareness and current knowledge of Parkinson\u2019s disease: a neurodegenerative disorder. Int J Neurosci. 2019;129(1):55\u201393.","journal-title":"Int J Neurosci"},{"issue":"1","key":"6354_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.28265","volume":"36","author":"N Dahodwala","year":"2021","unstructured":"Dahodwala N, Li P, Jahnke J, Ladage VP, Pettit AR, Kandukuri PL, et al. Burden of Parkinson\u2019s disease by severity: health care costs in the U.S. medicare population. Mov Disord. 2021;36(1):133\u201342.","journal-title":"Mov Disord"},{"issue":"7","key":"6354_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT. Parkinson\u2019s disease and Parkinsonism. Am J Med. 2019;132(7):802\u20137.","journal-title":"Am J Med"},{"issue":"7","key":"6354_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.parkreldis.2010.11.008","volume":"17","author":"S Bardien","year":"2011","unstructured":"Bardien S, Lesage S, Brice A, Carr J. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson\u2019s disease. Parkinsonism Relat Disord. 2011;17(7):501\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"15","key":"6354_CR6","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1074\/jbc.RA119.007631","volume":"294","author":"C-X Wu","year":"2019","unstructured":"Wu C-X, Liao J, Park Y, Reed X, Engel VA, Hoang NC, et al. Parkinson\u2019s disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics. J Biol Chem. 2019;294(15):5907\u201313.","journal-title":"J Biol Chem"},{"issue":"12","key":"6354_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nrn2935","volume":"11","author":"MR Cookson","year":"2010","unstructured":"Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson\u2019s disease. Nat Rev Neurosci. 2010;11(12):791\u20137.","journal-title":"Nat Rev Neurosci"},{"key":"6354_CR8","doi-asserted-by":"publisher","first-page":"105837","DOI":"10.1016\/j.nbd.2022.105837","volume":"173","author":"A Oun","year":"2022","unstructured":"Oun A, Sabogal-Guaqueta AM, Galuh S, Alexander A, Kortholt A, Dolga A. The multifaceted role of LRRK2 in Parkinson\u2019s disease: From human iPSC to organoids. Neurobiol Dis. 2022;173:105837.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"6354_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.stemcr.2019.01.020","volume":"12","author":"H Kim","year":"2019","unstructured":"Kim H, Park HJ, Choi H, Chang Y, Park H, Shin J, et al. Modeling G2019S-LRRK2 sporadic Parkinson\u2019s disease in 3D midbrain organoids. Stem Cell Reports. 2019;12(3):518\u201331.","journal-title":"Stem Cell Reports"},{"key":"6354_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fneur.2020.00395","volume":"11","author":"E Hustad","year":"2020","unstructured":"Hustad E, Aasly JO. Clinical and imaging markers of prodromal Parkinson\u2019s disease. Front Neurol. 2020;11:395.","journal-title":"Front Neurol"},{"issue":"1","key":"6354_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira A. Parkinson disease. Eur J Neurol. 2020;27(1):27\u201342.","journal-title":"Eur J Neurol"},{"issue":"12","key":"6354_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1055\/a-1460-8795","volume":"193","author":"S Aludin","year":"2021","unstructured":"Aludin S, Schmill LA. MRI signs of Parkinson\u2019s disease and atypical Parkinsonism. Rofo. 2021;193(12):1403\u201310.","journal-title":"Rofo"},{"issue":"3","key":"6354_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/ijms21030793","volume":"21","author":"T Yasuhara","year":"2020","unstructured":"Yasuhara T. Neurobiology research in Parkinson\u2019s disease. Int J Mol Sci. 2020;21(3):793.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"6354_CR14","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, Nalls MA, Hallgr\u00edmsd\u00f3ttir IB, Hunkapiller J, Van Der Brug M, Cai F, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet. 2017;49(10):1511\u20136.","journal-title":"Nat Genet"},{"issue":"6","key":"6354_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s13760-020-01473-5","volume":"120","author":"A Cherian","year":"2020","unstructured":"Cherian A, Divya K. Genetics of Parkinson\u2019s disease. Acta Neurol Belg. 2020;120(6):1297\u2013305.","journal-title":"Acta Neurol Belg"},{"key":"6354_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S. The clinical symptoms of Parkinson\u2019s disease. J Neurochem. 2016;139:318\u201324.","journal-title":"J Neurochem"},{"issue":"1","key":"6354_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","volume":"177","author":"G Sirugo","year":"2019","unstructured":"Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26\u201331.","journal-title":"Cell"},{"issue":"1","key":"6354_CR18","first-page":"1","volume":"1","author":"G Kannarkat","year":"2015","unstructured":"Kannarkat G, Cook D, Lee J, Chang J, Chung J, Sandy E, et al. Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson\u2019s disease: an observational and case\u2013control study. NPJ Parkinson\u2019s Disease. 2015;1(1):1\u20139.","journal-title":"NPJ Parkinson\u2019s Disease"},{"key":"6354_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-49969-7_1","volume":"14","author":"E Monfrini","year":"2017","unstructured":"Monfrini E, Fonzo AD. Leucine-rich repeat kinase (LRRK2) genetics and Parkinson\u2019s disease. Adv Neurobiol. 2017;14:3\u201330.","journal-title":"Adv Neurobiol"},{"issue":"6","key":"6354_CR20","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1002\/med.21718","volume":"40","author":"D Li","year":"2020","unstructured":"Li D, Mastaglia FL, Fletcher S, Wilton SD. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson\u2019s disease in the precision medicine era. Med Res Rev. 2020;40(6):2650\u201381.","journal-title":"Med Res Rev"},{"key":"6354_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ceb.2020.01.001","volume":"63","author":"M Taylor","year":"2020","unstructured":"Taylor M, Alessi DR. Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson\u2019s disease. Curr Opin Cell Biol. 2020;63:102\u201313.","journal-title":"Curr Opin Cell Biol"},{"issue":"8","key":"6354_CR22","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/bph.15575","volume":"179","author":"S Azeggagh","year":"2022","unstructured":"Azeggagh S, Berwick DC. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson\u2019s disease: the current state of play. Br J Pharmacol. 2022;179(8):1478\u201395.","journal-title":"Br J Pharmacol"},{"key":"6354_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fneur.2020.00682","volume":"11","author":"S Lesage","year":"2020","unstructured":"Lesage S, Houot M, Mangone G, Tesson C, Bertrand H, Forlani S, et al. Genetic and phenotypic basis of autosomal dominant Parkinson\u2019s disease in a large multi-center cohort. Front Neurol. 2020;11:682.","journal-title":"Front Neurol"},{"key":"6354_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.parkreldis.2022.05.012","volume":"98","author":"C Simpson","year":"2022","unstructured":"Simpson C, Vinikoor-Imler L, Nassan FL, Shirvan J, Lally C, Dam T, et al. Prevalence of ten LRRK2 variants in Parkinson\u2019s disease: a comprehensive review. Parkinsonism Relat Disord. 2022;98:108\u201313.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"6354_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s10038-020-0772-4","volume":"65","author":"Y Li","year":"2020","unstructured":"Li Y, Ikeda A, Yoshino H, Oyama G, Kitani M, Daida K, et al. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan. J Hum Genet. 2020;65(9):771\u201381.","journal-title":"J Hum Genet"},{"issue":"11","key":"6354_CR26","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/mds.28191","volume":"35","author":"Y Chen","year":"2020","unstructured":"Chen Y, Gu X, Ou R, Zhang L, Hou Y, Liu K, et al. Evaluating the role of SNCA, LRRK2, and GBA in Chinese patients with early-onset Parkinson\u2019s disease. Mov Disord. 2020;35(11):2046\u201355.","journal-title":"Mov Disord"},{"key":"6354_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fnagi.2019.00013","volume":"11","author":"L Shu","year":"2019","unstructured":"Shu L, Zhang Y, Sun Q, Pan H, Tang B. A comprehensive analysis of population differences in LRRK2 variant distribution in Parkinson\u2019s disease. Front Aging neurosci. 2019;11:13.","journal-title":"Front Aging neurosci"},{"issue":"2","key":"6354_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gendis.2019.01.004","volume":"6","author":"S Selvaraj","year":"2019","unstructured":"Selvaraj S, Piramanayagam S. Impact of gene mutation in the development of Parkinson\u2019s disease. Genes Dis. 2019;6(2):120\u20138.","journal-title":"Genes Dis"},{"issue":"4","key":"6354_CR29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s13311-014-0284-z","volume":"11","author":"IN Rudenko","year":"2014","unstructured":"Rudenko IN, Cookson MR. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics. 2014;11(4):738\u201350.","journal-title":"Neurotherapeutics"},{"issue":"18","key":"6354_CR30","doi-asserted-by":"publisher","first-page":"10161","DOI":"10.3390\/ijms221810161","volume":"22","author":"T Behl","year":"2021","unstructured":"Behl T, Madaan P, Sehgal A, Singh S, Sharma N, Bhatia S, et al. Elucidating the neuroprotective role of PPARs in Parkinson\u2019s disease: a neoteric and prospective target. Int J Mol Sci. 2021;22(18):10161.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6354_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/BJ20070209","volume":"405","author":"M Jaleel","year":"2007","unstructured":"Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson\u2019s disease mutants affect kinase activity. Biochem J. 2007;405(2):307\u201317.","journal-title":"Biochem J"},{"issue":"46","key":"6354_CR32","doi-asserted-by":"publisher","first-page":"16842","DOI":"10.1073\/pnas.0507360102","volume":"102","author":"AB West","year":"2005","unstructured":"West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci. 2005;102(46):16842\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"6354_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.tibs.2022.06.009","volume":"47","author":"Y Park","year":"2022","unstructured":"Park Y, Liao J, Hoang QQ. Roc, the G-domain of the Parkinson\u2019s disease-associated protein LRRK2. Trends Biochem Sci. 2022;47(12):1038\u201347.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"6354_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-023-00445-9","volume":"9","author":"J-M Taymans","year":"2023","unstructured":"Taymans J-M, Mutez E, Sibran W, Vandewynckel L, Deldycke C, Bleuse S, et al. Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson\u2019s disease and pharmacodynamic biomarkers. NPJ Parkinsons Dis. 2023;9(1):21.","journal-title":"NPJ Parkinsons Dis"},{"issue":"10","key":"6354_CR35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-019-01139-4","volume":"79","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Dzamko N. Recent developments in LRRK2-targeted therapy for Parkinson\u2019s disease. Drugs. 2019;79(10):1037\u201351.","journal-title":"Drugs"},{"issue":"1","key":"6354_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-10501-z","volume":"7","author":"K Thirstrup","year":"2017","unstructured":"Thirstrup K, D\u00e4chsel JC, Oppermann FS, Williamson DS, Smith GP, Fog K, et al. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. Sci Rep. 2017;7(1):1\u201318.","journal-title":"Sci Rep"},{"key":"6354_CR37","doi-asserted-by":"publisher","first-page":"e12813","DOI":"10.7554\/eLife.12813","volume":"5","author":"M Steger","year":"2016","unstructured":"Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016;5:e12813.","journal-title":"Elife"},{"key":"6354_CR38","doi-asserted-by":"publisher","first-page":"120806","DOI":"10.1016\/j.lfs.2022.120806","volume":"306","author":"J Liu","year":"2022","unstructured":"Liu J, Zheng X, Wu X. The Rab GTPase in the heart: Pivotal roles in development and disease. Life Sci. 2022;306:120806.","journal-title":"Life Sci"},{"key":"6354_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ceb.2019.03.009","volume":"59","author":"L Bonet-Ponce","year":"2019","unstructured":"Bonet-Ponce L, Cookson MR. The role of Rab GTPases in the pathobiology of Parkinson\u2019s disease. Curr Opin Cell Biol. 2019;59:73\u201380.","journal-title":"Curr Opin Cell Biol"},{"issue":"8","key":"6354_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrm2728","volume":"10","author":"H Stenmark","year":"2009","unstructured":"Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10(8):513\u201325.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6354_CR41","doi-asserted-by":"publisher","first-page":"e31012","DOI":"10.7554\/eLife.31012","volume":"6","author":"M Steger","year":"2017","unstructured":"Steger M, Diez F, Dhekne HS, Lis P, Nirujogi RS, Karayel O, et al. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife. 2017;6:e31012.","journal-title":"Elife"},{"issue":"6","key":"6354_CR42","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/1873-3468.14492","volume":"597","author":"SR Pfeffer","year":"2022","unstructured":"Pfeffer SR. LRRK2 phosphorylation of Rab GTPases in Parkinson\u2019s disease. FEBS Lett. 2022;597(6):811\u20138.","journal-title":"FEBS Lett"},{"issue":"17","key":"6354_CR43","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1042\/BCJ20160557","volume":"473","author":"G Ito","year":"2016","unstructured":"Ito G, Katsemonova K, Tonelli F, Lis P, Baptista MA, Shpiro N, et al. Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors. Biochem J. 2016;473(17):2671\u201385.","journal-title":"Biochem J"},{"issue":"164","key":"6354_CR44","doi-asserted-by":"publisher","first-page":"164ra161","DOI":"10.1126\/scitranslmed.3004485","volume":"4","author":"Z Sheng","year":"2012","unstructured":"Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med. 2012;4(164):164ra161.","journal-title":"Sci Transl Med"},{"issue":"2","key":"6354_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/hmg\/ddx410","volume":"27","author":"Z Liu","year":"2018","unstructured":"Liu Z, Bryant N, Kumaran R, Beilina A, Abeliovich A, Cookson MR, et al. LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum Mol Genet. 2018;27(2):385\u201395.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"6354_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.201798099","volume":"37","author":"E Purlyte","year":"2018","unstructured":"Purlyte E, Dhekne HS, Sarhan AR, Gomez R, Lis P, Wightman M, et al. Rab29 activation of the Parkinson\u2019s disease-associated LRRK2 kinase. EMBO J. 2018;37(1):1\u201318.","journal-title":"EMBO J"},{"issue":"1","key":"6354_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BCJ20170802","volume":"475","author":"P Lis","year":"2018","unstructured":"Lis P, Burel S, Steger M, Mann M, Brown F, Diez F, et al. Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson\u2019s disease kinase. Biochem J. 2018;475(1):1\u201322.","journal-title":"Biochem J"},{"issue":"1","key":"6354_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1042\/BJ20120637","volume":"446","author":"IN Rudenko","year":"2012","unstructured":"Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, et al. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson\u2019s disease is a partial loss-of-function mutation. Biochem J. 2012;446(1):99\u2013111.","journal-title":"Biochem J"},{"key":"6354_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fnins.2020.00443","volume":"14","author":"RL Wallings","year":"2020","unstructured":"Wallings RL, Herrick MK, Tansey MG. LRRK2 at the interface between peripheral and central immune function in Parkinson\u2019s. Front Neurosci. 2020;14:443.","journal-title":"Front Neurosci"},{"key":"6354_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3389\/fnins.2020.00865","volume":"14","author":"HJ Rideout","year":"2020","unstructured":"Rideout HJ, Chartier-Harlin M-C, Fell MJ, Hirst WD, Huntwork-Rodriguez S, Leyns CE, et al. The current state-of-the art of LRRK2-based biomarker assay development in Parkinson\u2019s disease. Front Neurosci. 2020;14:865.","journal-title":"Front Neurosci"},{"issue":"11","key":"6354_CR51","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3727\/096368916X691682","volume":"25","author":"R Gonzalez","year":"2016","unstructured":"Gonzalez R, Garitaonandia I, Poustovoitov M, Abramihina T, McEntire C, Culp B, et al. Neural stem cells derived from human parthenogenetic stem cells engraft and promote recovery in a nonhuman primate model of Parkinson\u2019s disease. Cell Transpl. 2016;25(11):1945\u201366.","journal-title":"Cell Transpl"},{"issue":"5","key":"6354_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063778","volume":"8","author":"F Giesert","year":"2013","unstructured":"Giesert F, Hofmann A, B\u00fcrger A, Zerle J, Kloos K, Hafen U, et al. Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS ONE. 2013;8(5): e63778.","journal-title":"PLoS ONE"},{"key":"6354_CR53","unstructured":"Levy DRS. Exploring the role of Leucine Rich Repeat Kinase 2 within the innate immune system. University of Cambridge; 2018."},{"key":"6354_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113245","volume":"214","author":"X Chen","year":"2021","unstructured":"Chen X, Zhang Q, Zhang Y, Fang J, Jiang D, Mou Z, et al. 18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson\u2019s disease. Eur J Med Chem. 2021;214: 113245.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"6354_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-022-00324-9","volume":"8","author":"SP Choudhury","year":"2022","unstructured":"Choudhury SP, Bano S, Sen S, Suchal K, Kumar S, Nikolajeff F, et al. Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):1\u201324.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"6354_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-022-00386-9","volume":"8","author":"PW-L Ho","year":"2022","unstructured":"Ho PW-L, Chang EE-S, Leung C-T, Liu H, Malki Y, Pang SY-Y, et al. Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain \u03b1-synuclein oligomers without adverse effects. NPJ Parkinsons Dis. 2022;8(1):1\u201322.","journal-title":"NPJ Parkinsons Dis"},{"issue":"8","key":"6354_CR57","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","volume":"22","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Cornblath EJ, Darwich A, Zhang B, Brown H, Gathagan RJ, et al. Spread of \u03b1-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat Neurosci. 2019;22(8):1248\u201357.","journal-title":"Nat Neurosci"},{"key":"6354_CR58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.67604","volume":"10","author":"F Singh","year":"2021","unstructured":"Singh F, Prescott AR, Rosewell P, Ball G, Reith AD, Ganley IG. Pharmacological rescue of impaired mitophagy in Parkinson\u2019s disease-related LRRK2 G2019S knock-in mice. Elife. 2021;10: e67604.","journal-title":"Elife"},{"issue":"6","key":"6354_CR59","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.neuron.2012.08.022","volume":"75","author":"S Matta","year":"2012","unstructured":"Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W, Miskiewicz K, et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron. 2012;75(6):1008\u201321.","journal-title":"Neuron"},{"issue":"24","key":"6354_CR60","first-page":"5365","volume":"25","author":"MS Islam","year":"2016","unstructured":"Islam MS, Nolte H, Jacob W, Ziegler AB, P\u00fctz S, Grosjean Y, et al. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson\u2019s disease. Hum Mol Genet. 2016;25(24):5365\u201382.","journal-title":"Hum Mol Genet"},{"key":"6354_CR61","doi-asserted-by":"publisher","first-page":"e12813","DOI":"10.7554\/eLife.12813","volume":"5","author":"M Steger","year":"2016","unstructured":"Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016;5:e12813.","journal-title":"Elife"},{"issue":"2","key":"6354_CR62","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BST20180462","volume":"47","author":"JH Kluss","year":"2019","unstructured":"Kluss JH, Mamais A, Cookson MR. LRRK2 links genetic and sporadic Parkinson\u2019s disease. Biochem Soc Trans. 2019;47(2):651\u201361.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"6354_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-019-0836-x","volume":"7","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Sengupta M, Trojanowski JQ, Lee VM. Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease. Acta Neuropathol Commun. 2019;7(1):1\u201316.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"6354_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","volume":"72","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE, Hazrati L-N, Fujioka S, Wszolek ZK, Dickson DW, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015;72(1):100\u20135.","journal-title":"JAMA Neurol"},{"issue":"3","key":"6354_CR65","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/jnc.14566","volume":"147","author":"RD Mills","year":"2018","unstructured":"Mills RD, Liang LY, Lio DSS, Mok YF, Mulhern TD, Cao G, et al. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties. J Neurochem. 2018;147(3):409\u201328.","journal-title":"J Neurochem"},{"issue":"13","key":"6354_CR66","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1016\/j.cell.2021.05.004","volume":"184","author":"A Myasnikov","year":"2021","unstructured":"Myasnikov A, Zhu H, Hixson P, Xie B, Yu K, Pitre A, et al. Structural analysis of the full-length human LRRK2. Cell. 2021;184(13):3519-27.e10.","journal-title":"Cell"},{"issue":"1","key":"6354_CR67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1042\/BJ20141095","volume":"465","author":"S Terheyden","year":"2015","unstructured":"Terheyden S, Ho FY, Gilsbach BK, Wittinghofer A, Kortholt A. Revisiting the Roco G-protein cycle. Biochem J. 2015;465(1):139\u201347.","journal-title":"Biochem J"},{"issue":"LRRK2","key":"6354_CR68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-319-49969-7_6","volume":"2","author":"L Civiero","year":"2017","unstructured":"Civiero L, Russo I, Bubacco L, Greggio E. Molecular insights and functional implication of LRRK2 dimerization. Leucine-Rich Repeat Kinase. 2017;2(LRRK2):107\u201321.","journal-title":"Leucine-Rich Repeat Kinase"},{"issue":"1","key":"6354_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01103-4","volume":"8","author":"E Deyaert","year":"2017","unstructured":"Deyaert E, Wauters L, Guaitoli G, Konijnenberg A, Leemans M, Terheyden S, et al. A homologue of the Parkinson\u2019s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover. Nat Commun. 2017;8(1):1\u201312.","journal-title":"Nat Commun"},{"key":"6354_CR70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.neuint.2018.03.001","volume":"117","author":"NA Kaidery","year":"2018","unstructured":"Kaidery NA, Thomas B. Current perspective of mitochondrial biology in Parkinson\u2019s disease. Neurochem Int. 2018;117:91\u2013113.","journal-title":"Neurochem Int"},{"key":"6354_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.freeradbiomed.2019.06.024","volume":"141","author":"B Chen","year":"2019","unstructured":"Chen B, Wen X, Jiang H, Wang J, Song N, Xie J. Interactions between iron and \u03b1-synuclein pathology in Parkinson\u2019s disease. Free Radical Biol Med. 2019;141:253\u201360.","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"6354_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0344-2","volume":"14","author":"DC Berwick","year":"2019","unstructured":"Berwick DC, Heaton GR, Azeggagh S, Harvey K. LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. Mol Neurodegener. 2019;14(1):1\u201322.","journal-title":"Mol Neurodegener"},{"issue":"7","key":"6354_CR73","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/jhg.2015.34","volume":"60","author":"L Pihlstr\u00f8m","year":"2015","unstructured":"Pihlstr\u00f8m L, Rengmark A, Bj\u00f8rnar\u00e5 KA, Dizdar N, Fardell C, Forsgren L, et al. Fine mapping and resequencing of the PARK16 locus in Parkinson\u2019s disease. J Hum Genet. 2015;60(7):357\u201362.","journal-title":"J Hum Genet"},{"key":"6354_CR74","unstructured":"Terheyden S. Structural and biochemical characterization of Roco proteins. 2018."},{"issue":"1","key":"6354_CR75","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.1073\/pnas.1312701111","volume":"111","author":"K Muda","year":"2014","unstructured":"Muda K, Bertinetti D, Gesellchen F, Hermann JS, von Zweydorf F, Geerlof A, et al. Parkinson-related LRRK2 mutation R1441C\/G\/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc Natl Acad Sci. 2014;111(1):E34\u201343.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"6354_CR76","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1042\/BJ20141305","volume":"469","author":"J Zhao","year":"2015","unstructured":"Zhao J, Molitor TP, Langston JW, Nichols RJ. LRRK2 dephosphorylation increases its ubiquitination. Biochem J. 2015;469(1):107\u201320.","journal-title":"Biochem J"},{"issue":"3","key":"6354_CR77","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.10113","volume":"51","author":"M Funayama","year":"2002","unstructured":"Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson\u2019s disease (PARK8) maps to chromosome 12p11.2\u2013q13.1. Ann Neurol. 2002;51(3):296\u2013301.","journal-title":"Ann Neurol"},{"key":"6354_CR78","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"EW Evans","year":"2004","unstructured":"Evans EW, Gilks WP, Simon J, van der Brug M, de Munain AL. Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron. 2004;44:595\u2013600.","journal-title":"Neuron"},{"issue":"1","key":"6354_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/380647","volume":"74","author":"A Zimprich","year":"2004","unstructured":"Zimprich A, M\u00fcller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet. 2004;74(1):11\u20139.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"6354_CR80","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ana.20484","volume":"57","author":"M Funayama","year":"2005","unstructured":"Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol. 2005;57(6):918\u201321.","journal-title":"Ann Neurol"},{"issue":"3","key":"6354_CR81","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.ejhg.5201539","volume":"14","author":"A Di Fonzo","year":"2006","unstructured":"Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Roh\u00e9 CF, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson\u2019s disease. Eur J Hum Genet. 2006;14(3):322\u201331.","journal-title":"Eur J Hum Genet"},{"key":"6354_CR82","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jnc.13593","volume":"139","author":"DG Hernandez","year":"2016","unstructured":"Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem. 2016;139:59\u201374.","journal-title":"J Neurochem"},{"issue":"3","key":"6354_CR83","doi-asserted-by":"publisher","first-page":"e1002548","DOI":"10.1371\/journal.pgen.1002548","volume":"8","author":"CM Lill","year":"2012","unstructured":"Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide B-MM, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson\u2019s disease genetics: the PDGene database. PLoS Genet. 2012;8(3):e1002548.","journal-title":"PLoS Genet"},{"issue":"7","key":"6354_CR84","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1212\/WNL.0b013e318264e353","volume":"79","author":"M Sharma","year":"2012","unstructured":"Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van Broeckhoven C, et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012;79(7):659\u201367.","journal-title":"Neurology"},{"issue":"1","key":"6354_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07340-5","volume":"9","author":"N Franceschini","year":"2018","unstructured":"Franceschini N, Giambartolomei C, De Vries PS, Finan C, Bis JC, Huntley RP, et al. GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. Nat Commun. 2018;9(1):1\u201314.","journal-title":"Nat Commun"},{"issue":"9","key":"6354_CR86","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat Genet. 2014;46(9):989\u201393.","journal-title":"Nat Genet"},{"key":"6354_CR87","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12402-017-0219-8","volume":"9","author":"Geissler J. International Parkinson Disease Genomics Consortium members, Romanos M, Gerlach M, Berg D, Schulte C","year":"2017","unstructured":"Geissler J. International Parkinson Disease Genomics Consortium members, Romanos M, Gerlach M, Berg D, Schulte C. No genetic association between attention-deficit\/hyperactivity disorder (ADHD) and Parkinson\u2019s disease in nine ADHD candidate SNPs. Atten Defic Hyperact Disord. 2017;9:121\u20137.","journal-title":"Atten Defic Hyperact Disord"},{"issue":"1","key":"6354_CR88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/mds.28347","volume":"36","author":"E Menozzi","year":"2020","unstructured":"Menozzi E, Macnaughtan J, Schapira AH. LRRK2 Parkinsonism: does the response to gut bacteria mitigate the neurological picture? Mov Disord. 2020;36(1):71\u20135.","journal-title":"Mov Disord"},{"issue":"2","key":"6354_CR89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JPD-130192","volume":"3","author":"C Paisan-Ruiz","year":"2013","unstructured":"Paisan-Ruiz C, Lewis PA, Singleton AB. LRRK2: cause, risk, and mechanism. J Parkinsons Dis. 2013;3(2):85\u2013103.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"6354_CR90","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s42003-022-04136-8","volume":"5","author":"HS Xenias","year":"2022","unstructured":"Xenias HS, Chen C, Kang S, Cherian S, Situ X, Shanmugasundaram B, et al. R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations. Commun Biol. 2022;5(1):1211.","journal-title":"Commun Biol"},{"issue":"1","key":"6354_CR91","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1212\/WNL.0000000000001708","volume":"85","author":"K Marder","year":"2015","unstructured":"Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A, et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 consortium. Neurology. 2015;85(1):89\u201395.","journal-title":"Neurology"},{"key":"6354_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105028","volume":"144","author":"T-I Kam","year":"2020","unstructured":"Kam T-I, Hinkle JT, Dawson TM, Dawson VL. Microglia and astrocyte dysfunction in Parkinson\u2019s disease. Neurobiol Dis. 2020;144: 105028.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"6354_CR93","first-page":"117","volume":"34","author":"VA Morais","year":"2022","unstructured":"Morais VA, Vos M. Reduced penetrance of Parkinson\u2019s disease models. Med Gen. 2022;34(2):117\u201324.","journal-title":"Med Gen"},{"issue":"11","key":"6354_CR94","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3390\/cells9112344","volume":"9","author":"L Iannotta","year":"2020","unstructured":"Iannotta L, Biosa A, Kluss JH, Tombesi G, Kaganovich A, Cogo S, et al. Divergent effects of G2019S and R1441C LRRK2 mutations on LRRK2 and Rab10 phosphorylations in mouse tissues. Cells. 2020;9(11):2344.","journal-title":"Cells"},{"key":"6354_CR95","doi-asserted-by":"publisher","first-page":"1016040","DOI":"10.3389\/fneur.2022.1016040","volume":"13","author":"RK Lesniak","year":"2022","unstructured":"Lesniak RK, Nichols RJ, Montine TJ. Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson\u2019s disease and other diseases for which carriers are at increased risk. Front Neurol. 2022;13:1016040.","journal-title":"Front Neurol"},{"key":"6354_CR96","doi-asserted-by":"publisher","first-page":"3418306","DOI":"10.1155\/2018\/3418306","volume":"2018","author":"W Di","year":"2018","unstructured":"Di W, Zeng Z, Li J, Liu X, Bo M, Lv H. The association between LRRK2 G2385R and phenotype of Parkinson\u2019s disease in Asian population: a meta-analysis of comparative studies. Parkinson\u2019s disease. 2018;2018:3418306.","journal-title":"Parkinson's disease"},{"issue":"9","key":"6354_CR97","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1111\/ene.15417","volume":"29","author":"P Wang","year":"2022","unstructured":"Wang P, Cui P, Luo Q, Chen J, Tang H, Zhang L, et al. Penetrance of Parkinson disease LRRK2 G2385R-associated variant in the Chinese population. Eur J Neurol. 2022;29(9):2639\u201344.","journal-title":"Eur J Neurol"},{"issue":"1","key":"6354_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-05760-9","volume":"7","author":"MDP Carrion","year":"2017","unstructured":"Carrion MDP, Marsicano S, Daniele F, Marte A, Pischedda F, Di Cairano E, et al. The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Sci Rep. 2017;7(1):1\u201315.","journal-title":"Sci Rep"},{"issue":"9","key":"6354_CR99","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1042\/BCJ20160909","volume":"474","author":"IN Rudenko","year":"2017","unstructured":"Rudenko IN, Kaganovich A, Langston RG, Beilina A, Ndukwe K, Kumaran R, et al. The G2385R risk factor for Parkinson\u2019s disease enhances CHIP-dependent intracellular degradation of LRRK2. Biochem J. 2017;474(9):1547\u201358.","journal-title":"Biochem J"},{"issue":"6","key":"6354_CR100","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s11064-018-2650-4","volume":"44","author":"RG Langston","year":"2019","unstructured":"Langston RG, Rudenko IN, Kumaran R, Hauser DN, Kaganovich A, Ponce LB, et al. Differences in stability, activity and mutation effects between human and mouse leucine-rich repeat kinase 2. Neurochem Res. 2019;44(6):1446\u201359.","journal-title":"Neurochem Res"},{"issue":"22","key":"6354_CR101","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1093\/hmg\/ddx320","volume":"26","author":"EH Howlett","year":"2017","unstructured":"Howlett EH, Jensen N, Belmonte F, Zafar F, Hu X, Kluss J, et al. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson\u2019s disease. Hum Mol Genet. 2017;26(22):4340\u201351.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"6354_CR102","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1073\/pnas.1817889116","volume":"116","author":"P Zhang","year":"2019","unstructured":"Zhang P, Fan Y, Ru H, Wang L, Magupalli VG, Taylor SS, et al. Crystal structure of the WD40 domain dimer of LRRK2. Proc Natl Acad Sci. 2019;116(5):1579\u201384.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"6354_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149739","volume":"11","author":"Y Shu","year":"2016","unstructured":"Shu Y, Ming J, Zhang P, Wang Q, Jiao F, Tian B. Parkinson-related LRRK2 mutation R1628P enables Cdk5 phosphorylation of LRRK2 and upregulates its kinase activity. PLoS ONE. 2016;11(3): e0149739.","journal-title":"PLoS ONE"},{"issue":"1","key":"6354_CR104","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1042\/BST20160264","volume":"45","author":"MS Islam","year":"2017","unstructured":"Islam MS, Moore DJ. Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation. Biochem Soc Trans. 2017;45(1):163\u201372.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"6354_CR105","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/jamaneurol.2017.3363","volume":"75","author":"B Xiao","year":"2018","unstructured":"Xiao B, Deng X, Ng EY-L, Allen JC, Lim S-Y, Ahmad-Annuar A, et al. Association of LRRK2 haplotype with age at onset in Parkinson disease. JAMA Neurol. 2018;75(1):127\u20138.","journal-title":"JAMA Neurol"},{"issue":"7","key":"6354_CR106","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/ene.12315","volume":"21","author":"M Bozi","year":"2014","unstructured":"Bozi M, Papadimitriou D, Antonellou R, Moraitou M, Maniati M, Vassilatis D, et al. Genetic assessment of familial and early-onset Parkinson\u2019s disease in a Greek population. Eur J Neurol. 2014;21(7):963\u20138.","journal-title":"Eur J Neurol"},{"key":"6354_CR107","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jns.2016.12.009","volume":"373","author":"F Peng","year":"2017","unstructured":"Peng F, Sun Y-M, Chen C, Luo S-S, Li D-K, Wang Y-X, et al. The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: a five-year follow-up and literatures review. J Neurol Sci. 2017;373:23\u20136.","journal-title":"J Neurol Sci"},{"issue":"13","key":"6354_CR108","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/mds.23265","volume":"25","author":"JO Aasly","year":"2010","unstructured":"Aasly JO, Vilari\u00f1o-G\u00fcell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, et al. Novel pathogenic LRRK2 p. Asn1437His substitution in familial Parkinson\u2019s disease. Mov Disord. 2010;25(13):2156\u201363.","journal-title":"Mov Disord"},{"issue":"5","key":"6354_CR109","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.parkreldis.2012.02.018","volume":"18","author":"E Yonova-Doing","year":"2012","unstructured":"Yonova-Doing E, Atadzhanov M, Quadri M, Kelly P, Shawa N, Musonda ST, et al. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(5):567\u201371.","journal-title":"Parkinsonism Relat Disord"},{"key":"6354_CR110","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2763838","author":"R Kaiyrzhanov","year":"2020","unstructured":"Kaiyrzhanov R, Aitkulova A, Shashkin C, Zharkinbekova N, Rizig M, Zholdybayeva E, et al. LRRK2 mutations and Asian disease-associated variants in the first parkinson\u2019s disease cohort from Kazakhstan. Parkinson\u2019s Dis. 2020. https:\/\/doi.org\/10.1155\/2020\/2763838.","journal-title":"Parkinson\u2019s Dis"},{"key":"6354_CR111","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.parkreldis.2019.07.032","volume":"66","author":"A Puschmann","year":"2019","unstructured":"Puschmann A, Jim\u00e9nez-Ferrer I, Lundblad-Andersson E, M\u00e5rtensson E, Hansson O, Odin P, et al. Low prevalence of known pathogenic mutations in dominant PD genes: a Swedish multicenter study. Parkinsonism Relat Disord. 2019;66:158\u201365.","journal-title":"Parkinsonism Relat Disord"},{"issue":"421","key":"6354_CR112","doi-asserted-by":"publisher","first-page":"eaai7635","DOI":"10.1126\/scitranslmed.aai7635","volume":"9","author":"KJ Ryan","year":"2017","unstructured":"Ryan KJ, White CC, Patel K, Xu J, Olah M, Replogle JM, et al. A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Sci Transl Med. 2017;9(421):eaai7635.","journal-title":"Sci Transl Med"},{"issue":"1","key":"6354_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18755-4","volume":"11","author":"V Panagiotakopoulou","year":"2020","unstructured":"Panagiotakopoulou V, Ivanyuk D, De Cicco S, Haq W, Arsi\u0107 A, Yu C, et al. Interferon-\u03b3 signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells. Nat Commun. 2020;11(1):1\u201317.","journal-title":"Nat Commun"},{"issue":"13","key":"6354_CR114","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1523\/JNEUROSCI.0650-14.2015","volume":"35","author":"JM Puccini","year":"2015","unstructured":"Puccini JM, Marker DF, Fitzgerald T, Barbieri J, Kim CS, Miller-Rhodes P, et al. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. J Neurosci. 2015;35(13):5271\u201383.","journal-title":"J Neurosci"},{"key":"6354_CR115","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fneur.2019.00218","volume":"10","author":"N Ball","year":"2019","unstructured":"Ball N, Teo W-P, Chandra S, Chapman J. Parkinson\u2019s disease and the environment. Front Neurol. 2019;10:218.","journal-title":"Front Neurol"},{"issue":"2","key":"6354_CR116","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 2020;19(2):170\u20138.","journal-title":"Lancet Neurol"},{"issue":"451","key":"6354_CR117","doi-asserted-by":"publisher","first-page":"eaar5429","DOI":"10.1126\/scitranslmed.aar5429","volume":"10","author":"R Di Maio","year":"2018","unstructured":"Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, et al. LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci Transl Med. 2018;10(451):eaar5429.","journal-title":"Sci Transl Med"},{"issue":"565","key":"6354_CR118","doi-asserted-by":"publisher","first-page":"eaay0399","DOI":"10.1126\/scitranslmed.aay0399","volume":"12","author":"C Kim","year":"2020","unstructured":"Kim C, Beilina A, Smith N, Li Y, Kim M, Kumaran R, et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Science Transl Med. 2020;12(565):eaay0399.","journal-title":"Science Transl Med"},{"key":"6354_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104626","volume":"134","author":"EM Rocha","year":"2020","unstructured":"Rocha EM, De Miranda BR, Castro S, Drolet R, Hatcher NG, Yao L, et al. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson\u2019s disease. Neurobiol Dis. 2020;134: 104626.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"6354_CR120","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/cells9051115","volume":"9","author":"G Lamonaca","year":"2020","unstructured":"Lamonaca G, Volta M. Alpha-synuclein and LRRK2 in synaptic autophagy: linking early dysfunction to late-stage pathology in Parkinson\u2019s disease. Cells. 2020;9(5):1115.","journal-title":"Cells"},{"issue":"32","key":"6354_CR121","doi-asserted-by":"publisher","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","volume":"290","author":"JP Daher","year":"2015","unstructured":"Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, et al. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates \u03b1-synuclein gene-induced neurodegeneration. J Biol Chem. 2015;290(32):19433\u201344.","journal-title":"J Biol Chem"},{"issue":"1","key":"6354_CR122","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s13311-022-01290-z","volume":"20","author":"M Volta","year":"2023","unstructured":"Volta M. Lysosomal pathogenesis of Parkinson\u2019s disease: insights From LRRK2 and GBA1 rodent models. Neurotherapeutics. 2023;20(1):127\u201339.","journal-title":"Neurotherapeutics"},{"issue":"9457","key":"6354_CR123","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(05)17829-5","volume":"365","author":"A Di Fonzo","year":"2005","unstructured":"Di Fonzo A, Roh\u00e9 CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson\u2019s disease. Lancet. 2005;365(9457):412\u20135.","journal-title":"Lancet"},{"issue":"10","key":"6354_CR124","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/biom11101419","volume":"11","author":"S Mehra","year":"2021","unstructured":"Mehra S, Gadhe L, Bera R, Sawner AS, Maji SK. Structural and functional insights into \u03b1-synuclein fibril polymorphism. Biomolecules. 2021;11(10):1419.","journal-title":"Biomolecules"},{"key":"6354_CR125","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3389\/fnins.2019.01352","volume":"13","author":"F Albanese","year":"2019","unstructured":"Albanese F, Novello S, Morari M. Autophagy and LRRK2 in the aging brain. Front Neurosci. 2019;13:1352.","journal-title":"Front Neurosci"},{"issue":"4","key":"6354_CR126","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.neuron.2016.09.037","volume":"92","author":"SF Soukup","year":"2016","unstructured":"Soukup SF, Kuenen S, Vanhauwaert R, Manetsberger J, Hern\u00e1ndez-D\u00edaz S, Swerts J, et al. A LRRK2-dependent EndophilinA phosphoswitch is critical for macroautophagy at presynaptic terminals. Neuron. 2016;92(4):829\u201344.","journal-title":"Neuron"},{"issue":"6","key":"6354_CR127","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ncb2979","volume":"16","author":"A Stolz","year":"2014","unstructured":"Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. Nat Cell Biol. 2014;16(6):495\u2013501.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"6354_CR128","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1016\/j.jmb.2019.10.013","volume":"432","author":"O Conway","year":"2020","unstructured":"Conway O, Akpinar HA, Rogov VV, Kirkin V. Selective autophagy receptors in neuronal health and disease. J Mol Biol. 2020;432(8):2483\u2013509.","journal-title":"J Mol Biol"},{"issue":"12","key":"6354_CR129","doi-asserted-by":"publisher","first-page":"e3001480","DOI":"10.1371\/journal.pbio.3001480","volume":"19","author":"A Mamais","year":"2021","unstructured":"Mamais A. Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia. PLoS Biol. 2021;19(12):e3001480.","journal-title":"PLoS Biol"},{"issue":"4","key":"6354_CR130","doi-asserted-by":"publisher","first-page":"692","DOI":"10.4161\/auto.19305","volume":"8","author":"P G\u00f3mez-Suaga","year":"2012","unstructured":"G\u00f3mez-Suaga P, Hilfiker S. LRRK2 as a modulator of lysosomal calcium homeostasis with downstream effects on autophagy. Autophagy. 2012;8(4):692\u20133.","journal-title":"Autophagy"},{"issue":"22","key":"6354_CR131","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1016\/j.jmb.2017.09.015","volume":"429","author":"SAH de Poot","year":"2017","unstructured":"de Poot SAH, Tian G, Finley D. Meddling with fate: the proteasomal deubiquitinating enzymes. J Mol Biol. 2017;429(22):3525\u201345.","journal-title":"J Mol Biol"},{"key":"6354_CR132","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-397863-9.00002-X","volume":"109","author":"N Chondrogianni","year":"2012","unstructured":"Chondrogianni N, Gonos ES. Structure and function of the ubiquitin-proteasome system: modulation of components. Prog Mol Biol Transl Sci. 2012;109:41\u201374.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"8","key":"6354_CR133","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/cddis.2011.81","volume":"2","author":"M Lichtenberg","year":"2011","unstructured":"Lichtenberg M, Mansilla A, Zecchini VR, Fleming A, Rubinsztein DC. The Parkinson\u2019s disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis. 2011;2(8):196.","journal-title":"Cell Death Dis"},{"issue":"8","key":"6354_CR134","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1073\/pnas.0810123106","volume":"106","author":"HS Ko","year":"2009","unstructured":"Ko HS, Bailey R, Smith WW, Liu Z, Shin JH, Lee YI, Zhang YJ, Jiang H, Ross CA, Moore DJ, Patterson C, Petrucelli L, Dawson TM, Dawson VL. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A. 2009;106(8):2897\u2013902.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"6354_CR135","doi-asserted-by":"publisher","first-page":"e5949","DOI":"10.1371\/journal.pone.0005949","volume":"4","author":"X Ding","year":"2009","unstructured":"Ding X, Goldberg MS. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS ONE. 2009;4(6):e5949.","journal-title":"PLoS ONE"},{"issue":"2","key":"6354_CR136","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JPD-130192","volume":"3","author":"C Pais\u00e1n-Ruiz","year":"2013","unstructured":"Pais\u00e1n-Ruiz C, Lewis PA, Singleton AB. LRRK2: cause, risk, and mechanism. J Parkinsons Dis. 2013;3(2):85\u2013103.","journal-title":"J Parkinsons Dis"},{"key":"6354_CR137","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/jnr.21622","volume":"86","author":"P Gandhi","year":"2008","unstructured":"Gandhi P, Wang X, Zhu X, Chen S, Wilson-Delfosse A. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res. 2008;86:1711\u201320.","journal-title":"J Neurosci Res"},{"issue":"5","key":"6354_CR138","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/j.1471-4159.2009.06235.x","volume":"110","author":"F Gillardon","year":"2009","unstructured":"Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability\u2013a point of convergence in parkinsonian neurodegeneration? J Neurochem. 2009;110(5):1514\u201322.","journal-title":"J Neurochem"},{"issue":"18","key":"6354_CR139","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1093\/hmg\/ddy232","volume":"27","author":"L Pellegrini","year":"2018","unstructured":"Pellegrini L, Hauser DN, Li Y, Mamais A, Beilina A, Kumaran R, et al. Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice. Hum Mol Genet. 2018;27(18):3257\u201371.","journal-title":"Hum Mol Genet"},{"key":"6354_CR140","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1038\/ncomms6245","volume":"5","author":"VK Godena","year":"2014","unstructured":"Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun. 2014;5:5245.","journal-title":"Nat Commun"},{"issue":"7","key":"6354_CR141","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares M, I Rojo A, Manda G, Bosc\u00e1 L, Cuadrado A. Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells. 2020;9(7):1687.","journal-title":"Cells"},{"issue":"7","key":"6354_CR142","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jamaneurol.2017.0469","volume":"74","author":"A Witoelar","year":"2017","unstructured":"Witoelar A, Jansen IE, Wang Y, Desikan RS, Gibbs JR, Blauwendraat C, et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74(7):780\u201392.","journal-title":"JAMA Neurol"},{"issue":"1","key":"6354_CR143","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12974-016-0761-x","volume":"13","author":"RL de Maturana","year":"2016","unstructured":"de Maturana RL, Lang V, Zubiarrain A, Sousa A, V\u00e1zquez N, Gorostidi A, et al. Mutations in LRRK2 impair NF-\u03baB pathway in iPSC-derived neurons. J Neuroinflammation. 2016;13(1):295.","journal-title":"J Neuroinflammation"},{"issue":"25","key":"6354_CR144","doi-asserted-by":"publisher","first-page":"9289","DOI":"10.1073\/pnas.1403215111","volume":"111","author":"JP Daher","year":"2014","unstructured":"Daher JP, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB. Abrogation of \u03b1-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A. 2014;111(25):9289\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"6354_CR145","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","volume":"32","author":"MS Moehle","year":"2012","unstructured":"Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012;32(5):1602\u201311.","journal-title":"J Neurosci"},{"issue":"141","key":"6354_CR146","doi-asserted-by":"publisher","first-page":"141ra90","DOI":"10.1126\/scitranslmed.3003985","volume":"4","author":"O Cooper","year":"2012","unstructured":"Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson\u2019s disease. Sci Transl Med. 2012;4(141):141ra90.","journal-title":"Sci Transl Med"},{"issue":"22","key":"6354_CR147","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e3181ff9685","volume":"75","author":"H Mortiboys","year":"2010","unstructured":"Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology. 2010;75(22):2017\u201320.","journal-title":"Neurology"},{"issue":"5","key":"6354_CR148","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/ana.21019","volume":"60","author":"S Biskup","year":"2006","unstructured":"Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol. 2006;60(5):557\u201369.","journal-title":"Ann Neurol"},{"key":"6354_CR149","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.brainres.2018.06.010","volume":"1702","author":"A Singh","year":"2019","unstructured":"Singh A, Zhi L, Zhang H. LRRK2 and mitochondria: recent advances and current views. Brain Res. 2019;1702:96\u2013104.","journal-title":"Brain Res"},{"issue":"4","key":"6354_CR150","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tibs.2020.11.007","volume":"46","author":"AB Malpartida","year":"2021","unstructured":"Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Mitochondrial dysfunction and mitophagy in Parkinson\u2019s disease: from mechanism to therapy. Trends Biochem Sci. 2021;46(4):329\u201343.","journal-title":"Trends Biochem Sci"},{"issue":"15","key":"6354_CR151","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1074\/jbc.R112.420752","volume":"288","author":"M Patron","year":"2013","unstructured":"Patron M, Raffaello A, Granatiero V, Tosatto A, Merli G, De Stefani D, et al. The mitochondrial calcium uniporter (MCU): molecular identity and physiological roles. J Biol Chem. 2013;288(15):10750\u20138.","journal-title":"J Biol Chem"},{"issue":"5","key":"6354_CR152","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.molmet.2014.05.004","volume":"3","author":"RA Egnatchik","year":"2014","unstructured":"Egnatchik RA, Leamy AK, Jacobson DA, Shiota M, Young JD. ER calcium release promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate overload. Mol Metab. 2014;3(5):544\u201353.","journal-title":"Mol Metab"},{"key":"6354_CR153","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fnmol.2016.00035","volume":"9","author":"C Bedford","year":"2016","unstructured":"Bedford C, Sears C, Perez-Carrion M, Piccoli G, Condliffe SB. LRRK2 regulates voltage-gated calcium channel function. Front Mol Neurosci. 2016;9:35.","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"6354_CR154","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1080\/15548627.2017.1317913","volume":"13","author":"P Gomez-Suaga","year":"2017","unstructured":"Gomez-Suaga P, Paillusson S, Miller CCJ. ER-mitochondria signaling regulates autophagy. Autophagy. 2017;13(7):1250\u20131.","journal-title":"Autophagy"},{"issue":"6","key":"6354_CR155","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.stemcr.2015.11.004","volume":"5","author":"AJ Schwab","year":"2015","unstructured":"Schwab AJ, Ebert AD. Neurite aggregation and calcium dysfunction in iPSC-derived sensory neurons with Parkinson\u2019s disease-related LRRK2 G2019S mutation. Stem Cell Report. 2015;5(6):1039\u201352.","journal-title":"Stem Cell Report"},{"key":"6354_CR156","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.nbd.2015.02.031","volume":"78","author":"M Yue","year":"2015","unstructured":"Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172\u201395.","journal-title":"Neurobiol Dis"},{"issue":"37","key":"6354_CR157","doi-asserted-by":"publisher","first-page":"9302","DOI":"10.1002\/anie.201204589","volume":"51","author":"D Wang","year":"2012","unstructured":"Wang D, Wang J, Bonamy GM, Meeusen S, Brusch RG, Turk C, et al. A small molecule promotes mitochondrial fusion in mammalian cells. Angew Chem Int Ed Engl. 2012;51(37):9302\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"6354_CR158","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1590\/1980-57642016dn11-020012","volume":"11","author":"E Engelhardt","year":"2017","unstructured":"Engelhardt E, Gomes MDM. Lewy and his inclusion bodies: discovery and rejection. Dement Neuropsychol. 2017;11(2):198\u2013201.","journal-title":"Dement Neuropsychol"},{"issue":"1","key":"6354_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16(1):1\u201324.","journal-title":"Mol Neurodegener"},{"key":"6354_CR160","doi-asserted-by":"publisher","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","volume":"709","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Trojanowski JQ, Lee VM-Y. \u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies. Neuroscience Lett. 2019;709:134316.","journal-title":"Neuroscience Lett"},{"issue":"5999","key":"6354_CR161","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9 J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S\u00fcdhof TC. \u03b1-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329(5999):1663\u20137.","journal-title":"Science"},{"issue":"17","key":"6354_CR162","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355.","journal-title":"Neurology"},{"issue":"4","key":"6354_CR163","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00109-012-0984-y","volume":"91","author":"PS Guerreiro","year":"2013","unstructured":"Guerreiro PS, Huang Y, Gysbers A, Cheng D, Gai WP, Outeiro TF, et al. LRRK2 interactions with \u03b1-synuclein in Parkinson\u2019s disease brains and in cell models. J Mol Med (Berl). 2013;91(4):513\u201322.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"6354_CR164","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41531-022-00380-1","volume":"8","author":"L Fonseca-Ornelas","year":"2022","unstructured":"Fonseca-Ornelas L, Stricker JMS, Soriano-Cruz S, Weykopf B, Dettmer U, Muratore CR, et al. Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous \u03b1-synuclein in human neurons. NPJ Parkinson\u2019s Dis. 2022;8(1):118.","journal-title":"NPJ Parkinson's Dis"},{"issue":"3","key":"6354_CR165","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1365-2990.2007.00888.x","volume":"34","author":"J Alegre-Abarrategui","year":"2008","unstructured":"Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson\u2019s disease. Neuropathol Appl Neurobiol. 2008;34(3):272\u201383.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"6354_CR166","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cellsig.2010.01.006","volume":"22","author":"I Carballo-Carbajal","year":"2010","unstructured":"Carballo-Carbajal I, Weber-Endress S, Rovelli G, Chan D, Wolozin B, Klein CL, et al. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal. 2010;22(5):821\u20137.","journal-title":"Cell Signal"},{"issue":"1","key":"6354_CR167","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2009.06.142","volume":"387","author":"H Qing","year":"2009","unstructured":"Qing H, Wong W, McGeer EG, McGeer PL. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun. 2009;387(1):149\u201352.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"6354_CR168","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s11596-018-1977-z","volume":"38","author":"D Hu","year":"2018","unstructured":"Hu D, Niu JY, Xiong J, Nie SK, Zeng F, Zhang ZH. LRRK2 G2019S mutation inhibits degradation of \u03b1-synuclein in an in vitro model of Parkinson\u2019s disease. Curr Med Sci. 2018;38(6):1012\u20137.","journal-title":"Curr Med Sci"},{"issue":"1","key":"6354_CR169","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41531-022-00367-y","volume":"8","author":"T Tezuka","year":"2022","unstructured":"Tezuka T, Taniguchi D, Sano M, Shimada T, Oji Y, Tsunemi T, et al. Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis. 2022;8(1):97.","journal-title":"NPJ Parkinson's Dis"},{"issue":"1","key":"6354_CR170","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/hmg\/ddx389","volume":"27","author":"APT Nguyen","year":"2018","unstructured":"Nguyen APT, Daniel G, Vald\u00e9s P, Islam MS, Schneider BL, Moore DJ. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. Hum Mol Genet. 2018;27(1):120\u201334.","journal-title":"Hum Mol Genet"},{"key":"6354_CR171","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.neurobiolaging.2020.09.006","volume":"96","author":"S Castro-S\u00e1nchez","year":"2020","unstructured":"Castro-S\u00e1nchez S, Zaldivar-Diez J, Luengo E, L\u00f3pez MG, Gil C, Mart\u00ednez A, et al. Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Neurobiol Aging. 2020;96:148\u201354.","journal-title":"Neurobiol Aging"},{"issue":"8","key":"6354_CR172","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/mds.29449","volume":"38","author":"J Agin-Liebes","year":"2023","unstructured":"Agin-Liebes J, Hickman R, Vonsattel JP, Flowers X, Mayeux R, Surface M, et al. Patterns of TDP-43 deposition in brains with LRRK2 G2019S mutations. Mov Disord. 2023;38(8):1541\u20135.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"6354_CR173","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/jnc.13266","volume":"139 Suppl 1","author":"A Beilina","year":"2016","unstructured":"Beilina A, Cookson MR. Genes associated with Parkinson\u2019s disease: regulation of autophagy and beyond. J Neurochem. 2016;139 Suppl 1(Suppl 1):91\u2013107.","journal-title":"J Neurochem"},{"issue":"11","key":"6354_CR174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277658","volume":"17","author":"BV Dieriks","year":"2022","unstructured":"Dieriks BV, Highet B, Alik A, Bellande T, Stevenson TJ, Low V, et al. Human pericytes degrade diverse \u03b1-synuclein aggregates. PLoS ONE. 2022;17(11): e0277658.","journal-title":"PLoS ONE"},{"key":"6354_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.630743","volume":"12","author":"J Auzmendi-Iriarte","year":"2021","unstructured":"Auzmendi-Iriarte J, Matheu A. Impact of chaperone-mediated autophagy in brain aging: neurodegenerative diseases and glioblastoma. Front Aging Neurosci. 2021;12: 630743.","journal-title":"Front Aging Neurosci"},{"key":"6354_CR176","doi-asserted-by":"publisher","first-page":"902191","DOI":"10.3389\/fnagi.2022.902191","volume":"14","author":"MK Pandey","year":"2022","unstructured":"Pandey MK. The role of alpha-synuclein autoantibodies in the induction of brain inflammation and neurodegeneration in aged humans. Front Aging Neurosci. 2022;14:902191.","journal-title":"Front Aging Neurosci"},{"key":"6354_CR177","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/jnc.13266","volume":"139","author":"A Beilina","year":"2016","unstructured":"Beilina A, Cookson MR. Genes associated with Parkinson\u2019s disease: regulation of autophagy and beyond. J Neurochem. 2016;139:91\u2013107.","journal-title":"J Neurochem"},{"key":"6354_CR178","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.parkreldis.2017.12.007","volume":"48","author":"C Kessler","year":"2018","unstructured":"Kessler C, Atasu B, Hanagasi H, Sim\u00f3n-S\u00e1nchez J, Hauser A-K, Pak M, et al. Role of LRRK2 and SNCA in autosomal dominant Parkinson\u2019s disease in Turkey. Parkinsonism Relat Disord. 2018;48:34\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"6354_CR179","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s11481-020-09909-8","volume":"15","author":"T Ikezu","year":"2020","unstructured":"Ikezu T, Koro L, Wolozin B, Farraye FA, Strongosky AJ, Wszolek ZK. Crohn\u2019s and Parkinson\u2019s disease-associated LRRK2 mutations alter Type II interferon responses in human CD14(+) blood monocytes ex vivo. J Neuroimmune Pharmacol. 2020;15(4):794\u2013800.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"3","key":"6354_CR180","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/mds.27601","volume":"34","author":"F Atashrazm","year":"2019","unstructured":"Atashrazm F, Hammond D, Perera G, Bolliger MF, Matar E, Halliday GM, et al. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson\u2019s disease patients. Mov Disord. 2019;34(3):406\u201315.","journal-title":"Mov Disord"},{"issue":"1","key":"6354_CR181","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1042\/BCJ20170803","volume":"475","author":"Y Fan","year":"2018","unstructured":"Fan Y, Howden AJ, Sarhan AR, Lis P, Ito G, Martinez TN, et al. Interrogating Parkinson\u2019s disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J. 2018;475(1):23\u201344.","journal-title":"Biochem J"},{"issue":"1","key":"6354_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-016-0396-2","volume":"4","author":"C Bliederhaeuser","year":"2016","unstructured":"Bliederhaeuser C, Zondler L, Grozdanov V, Ruf WP, Brenner D, Melrose HL, et al. LRRK2 contributes to monocyte dysregulation in Parkinson\u2019s disease. Acta Neuropathol Commun. 2016;4(1):1\u20135.","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"6354_CR183","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.4049\/jimmunol.1000548","volume":"185","author":"A Gardet","year":"2010","unstructured":"Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, et al. LRRK2 is involved in the IFN-\u03b3 response and host response to pathogens. J Immunol. 2010;185(9):5577\u201385.","journal-title":"J Immunol"},{"key":"6354_CR184","first-page":"2015","volume-title":"Interferon gamma induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5: Dissertation","author":"M Ku\u00df","year":"2015","unstructured":"Ku\u00df M. Interferon gamma induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5: Dissertation. T\u00fcbingen: Universit\u00e4t T\u00fcbingen; 2015. p. 2015."},{"issue":"5","key":"6354_CR185","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00702-011-0653-2","volume":"118","author":"M Hakimi","year":"2011","unstructured":"Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, et al. Parkinson\u2019s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm. 2011;118(5):795\u2013808.","journal-title":"J Neural Transm"},{"issue":"1","key":"6354_CR186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-016-0004-y","volume":"3","author":"D Cook","year":"2017","unstructured":"Cook D, Kannarkat G, Cintron A, Butkovich LM, Fraser KB, Chang J, et al. LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis. 2017;3(1):1\u201312.","journal-title":"NPJ Parkinson's Dis"},{"issue":"6","key":"6354_CR187","doi-asserted-by":"publisher","first-page":"21519","DOI":"10.1371\/journal.pone.0021519","volume":"6","author":"J Th\u00e9venet","year":"2011","unstructured":"Th\u00e9venet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE. 2011;6(6):21519.","journal-title":"PLoS ONE"},{"issue":"444","key":"6354_CR188","doi-asserted-by":"publisher","first-page":"eaan8162","DOI":"10.1126\/scitranslmed.aan8162","volume":"10","author":"T Takagawa","year":"2018","unstructured":"Takagawa T, Kitani A, Fuss I, Levine B, Brant SR, Peter I, et al. An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci Transl Med. 2018;10(444):eaan8162.","journal-title":"Sci Transl Med"},{"issue":"1","key":"6354_CR189","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneumeth.2012.12.015","volume":"214","author":"F Gillardon","year":"2013","unstructured":"Gillardon F, Kremmer E, Froehlich T, Ueffing M, Hengerer B, Gloeckner CJ. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2? J Neurosci Method. 2013;214(1):62\u20138.","journal-title":"J Neurosci Method"},{"issue":"31","key":"6354_CR190","doi-asserted-by":"publisher","first-page":"15616","DOI":"10.1073\/pnas.1901805116","volume":"116","author":"VM Fava","year":"2019","unstructured":"Fava VM, Xu YZ, Lettre G, Van Thuc N, Orlova M, Thai VH, et al. Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson\u2019s disease. Proc Natl Acad Sci. 2019;116(31):15616\u201324.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"6354_CR191","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s11481-020-09909-8","volume":"15","author":"T Ikezu","year":"2020","unstructured":"Ikezu T, Koro L, Wolozin B, Farraye FA, Strongosky AJ, Wszolek ZK. Crohn\u2019s and Parkinson\u2019s disease-associated LRRK2 mutations alter type II interferon responses in human CD14+ blood monocytes ex vivo. J Neuroimmune Pharmacol. 2020;15(4):794\u2013800.","journal-title":"J Neuroimmune Pharmacol"},{"key":"6354_CR192","unstructured":"Fernandez-Hernandez H. The Role of LRRK2 in Crohn's Disease: Icahn School of Medicine at Mount Sinai; 2018."},{"issue":"6","key":"6354_CR193","doi-asserted-by":"publisher","first-page":"e91917","DOI":"10.1172\/jci.insight.91917","volume":"2","author":"T-C Liu","year":"2017","unstructured":"Liu T-C, Naito T, Liu Z, VanDussen KL, Haritunians T, Li D, et al. LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn\u2019s disease patients. JCI Insight. 2017;2(6):e91917.","journal-title":"JCI Insight."},{"issue":"1","key":"6354_CR194","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0306-4522(90)90229-W","volume":"39","author":"LJ Lawson","year":"1990","unstructured":"Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39(1):151\u201370.","journal-title":"Neuroscience"},{"issue":"9","key":"6354_CR195","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009373","volume":"2","author":"VH Perry","year":"2012","unstructured":"Perry VH. Innate inflammation in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2(9): a009373.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7638","key":"6354_CR196","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481\u20137.","journal-title":"Nature"},{"issue":"12","key":"6354_CR197","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798694","volume":"37","author":"A H\u00e4rtlova","year":"2018","unstructured":"H\u00e4rtlova A, Herbst S, Peltier J, Rodgers A, Bilkei-Gorzo O, Fearns A, et al. LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages. EMBO J. 2018;37(12): e98694.","journal-title":"EMBO J"},{"issue":"22","key":"6354_CR198","doi-asserted-by":"publisher","first-page":"E5164","DOI":"10.1073\/pnas.1718946115","volume":"115","author":"KS Kim","year":"2018","unstructured":"Kim KS, Marcogliese PC, Yang J, Callaghan SM, Resende V, Abdel-Messih E, et al. Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease. Proc Natl Acad Sci. 2018;115(22):E5164\u201373.","journal-title":"Proc Natl Acad Sci"},{"key":"6354_CR199","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nbd.2019.05.012","volume":"129","author":"I Russo","year":"2019","unstructured":"Russo I, Kaganovich A, Ding J, Landeck N, Mamais A, Varanita T, et al. Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory-and oxidative stress-related pathways upon treatment with \u03b1-synuclein fibrils. Neurobiol Dis. 2019;129:67\u201378.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"6354_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-015-0449-7","volume":"12","author":"I Russo","year":"2015","unstructured":"Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L, et al. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-\u03baB p50 signaling in cultured microglia cells. J Neuroinflammation. 2015;12(1):1\u201313.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"6354_CR201","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1042\/BST20160262","volume":"45","author":"H Lee","year":"2017","unstructured":"Lee H, James WS, Cowley SA. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson\u2019s disease. Biochem Soc Trans. 2017;45(1):131\u20139.","journal-title":"Biochem Soc Trans"},{"issue":"444","key":"6354_CR202","doi-asserted-by":"publisher","first-page":"eaan8162","DOI":"10.1126\/scitranslmed.aan8162","volume":"10","author":"T Takagawa","year":"2018","unstructured":"Takagawa T, Kitani A, Fuss I, Levine B, Brant SR, Peter I, et al. An increase in LRRK2 suppresses autophagy and enhances Dectin-1\u2013induced immunity in a mouse model of colitis. Sci Transl Med. 2018;10(444):eaan8162.","journal-title":"Sci Transl Med"},{"issue":"15","key":"6354_CR203","doi-asserted-by":"publisher","first-page":"24449","DOI":"10.18632\/oncotarget.15511","volume":"8","author":"S Wang","year":"2017","unstructured":"Wang S, Zhang X, Guo Y, Rong H, Liu T. The long noncoding RNA HOTAIR promotes Parkinson\u2019s disease by upregulating LRRK2 expression. Oncotarget. 2017;8(15):24449.","journal-title":"Oncotarget"},{"issue":"2","key":"6354_CR204","first-page":"563","volume":"10","author":"Q Chen","year":"2018","unstructured":"Chen Q, Huang X, Li R. lncRNA MALAT1\/miR-205-5p axis regulates MPP+-induced cell apoptosis in MN9D cells by directly targeting LRRK2. Am J Transl Res. 2018;10(2):563.","journal-title":"Am J Transl Res"},{"issue":"19","key":"6354_CR205","doi-asserted-by":"publisher","first-page":"11744","DOI":"10.3390\/ijms231911744","volume":"23","author":"AI Ravinther","year":"2022","unstructured":"Ravinther AI, Dewadas HD, Tong SR, Foo CN, Lin Y-E, Chien C-T, et al. Molecular pathways involved in LRRK2-linked Parkinson\u2019s disease: a systematic review. Int J Mol Sci. 2022;23(19):11744.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"6354_CR206","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.1021\/acs.jmedchem.4c00520","volume":"67","author":"K Kim","year":"2024","unstructured":"Kim K, Jang A, Shin H, Ye I, Lee JE, Kim T, et al. Concurrent optimizations of efficacy and blood-brain barrier permeability in new macrocyclic LRRK2 inhibitors for potential Parkinson\u2019s disease therapeutics. J Med Chem. 2024;67(9):7647\u201362.","journal-title":"J Med Chem"},{"issue":"3","key":"6354_CR207","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192497","volume":"13","author":"L Marrone","year":"2018","unstructured":"Marrone L, Bus C, Sch\u00f6ndorf D, Fitzgerald JC, K\u00fcbler M, Schmid B, et al. Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson\u2019s disease. PLoS ONE. 2018;13(3): e0192497.","journal-title":"PLoS ONE"},{"issue":"141","key":"6354_CR208","doi-asserted-by":"publisher","first-page":"141ra90","DOI":"10.1126\/scitranslmed.3003985","volume":"4","author":"O Cooper","year":"2012","unstructured":"Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson\u2019s disease. Sci Transl Med. 2012;4(141):141ra90.","journal-title":"Sci Transl Med"},{"issue":"28","key":"6354_CR209","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1523\/JNEUROSCI.3642-15.2016","volume":"36","author":"LA Volpicelli-Daley","year":"2016","unstructured":"Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JPL, Milnerwood AJ, et al. G2019S-LRRK2 expression augments \u03b1-synuclein sequestration into inclusions in neurons. J Neurosci. 2016;36(28):7415\u201327.","journal-title":"J Neurosci"},{"issue":"1","key":"6354_CR210","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5607\/en23023","volume":"33","author":"J-A Hwang","year":"2024","unstructured":"Hwang J-A, Choi SK, Kim SH, Kim DW. Pharmacological inhibition of LRRK2 exhibits neuroprotective activity in mouse photothrombotic stroke model. Exp Neurobiol. 2024;33(1):36.","journal-title":"Exp Neurobiol"},{"issue":"38","key":"6354_CR211","doi-asserted-by":"publisher","first-page":"2105152","DOI":"10.1002\/adfm.202105152","volume":"31","author":"W Cui","year":"2021","unstructured":"Cui W, Yang X, Chen X, Xiao D, Zhu J, Zhang M, et al. Treating LRRK2-related Parkinson\u2019s disease by inhibiting the mTOR signaling pathway to restore autophagy. Adv Func Mater. 2021;31(38):2105152.","journal-title":"Adv Func Mater"},{"key":"6354_CR212","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135426","volume":"740","author":"S Kesh","year":"2021","unstructured":"Kesh S, Kannan RR, Sivaji K, Balakrishnan A. Hesperidin downregulates kinases lrrk2 and gsk3\u03b2 in a 6-OHDA induced Parkinson\u2019s disease model. Neurosci Lett. 2021;740: 135426.","journal-title":"Neurosci Lett"},{"issue":"10","key":"6354_CR213","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.1002\/jcp.29632","volume":"235","author":"JM Thomas","year":"2020","unstructured":"Thomas JM, Wang X, Guo G, Li T, Dai B, Nucifora LG, et al. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions. J Cell Physiol. 2020;235(10):7309\u201320.","journal-title":"J Cell Physiol"},{"key":"6354_CR214","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fnagi.2016.00337","volume":"8","author":"JM Thomas","year":"2017","unstructured":"Thomas JM, Li T, Yang W, Xue F, Fishman PS, Smith WW. 68 and FX2149 attenuate mutant LRRK2-R1441C-induced neural transport impairment. Front Aging Neurosci. 2017;8:337.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"6354_CR215","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/mds.27994","volume":"35","author":"A Sanyal","year":"2020","unstructured":"Sanyal A, DeAndrade MP, Novis HS, Lin S, Chang J, Lengacher N, et al. Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition. Mov Disord. 2020;35(5):760\u201373.","journal-title":"Mov Disord"},{"key":"6354_CR216","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3389\/fnins.2020.00442","volume":"14","author":"A Sanyal","year":"2020","unstructured":"Sanyal A, Novis HS, Gasser E, Lin S, LaVoie MJ. LRRK2 kinase inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-derived neurons. Front Neurosci. 2020;14:442.","journal-title":"Front Neurosci"},{"issue":"1","key":"6354_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13413-w","volume":"10","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein D, Nguyen M, Young TJ, Severino A, Schwake M, Merchant K, et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat Commun. 2019;10(1):1\u20139.","journal-title":"Nat Commun"},{"issue":"1","key":"6354_CR218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-021-00272-w","volume":"8","author":"M Kedariti","year":"2022","unstructured":"Kedariti M, Frattini E, Baden P, Cogo S, Civiero L, Ziviani E, et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis. 2022;8(1):1\u201314.","journal-title":"NPJ Parkinson's Dis"},{"issue":"1","key":"6354_CR219","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.stemcr.2018.11.021","volume":"12","author":"JA Korecka","year":"2019","unstructured":"Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, et al. Neurite collapse and altered ER Ca2+ control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation. Stem Cell Report. 2019;12(1):29\u201341.","journal-title":"Stem Cell Report"},{"issue":"6","key":"6354_CR220","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.cmet.2019.08.023","volume":"30","author":"C-H Hsieh","year":"2019","unstructured":"Hsieh C-H, Li L, Vanhauwaert R, Nguyen KT, Davis MD, Bu G, et al. Miro1 marks Parkinson\u2019s disease subset and Miro1 reducer rescues neuron loss in Parkinson\u2019s models. Cell Metab. 2019;30(6):1131-40.e7.","journal-title":"Cell Metab"},{"issue":"5","key":"6354_CR221","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-015-1487-z","volume":"130","author":"H Radford","year":"2015","unstructured":"Radford H, Moreno JA, Verity N, Halliday M, Mallucci GR. PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol. 2015;130(5):633\u201342.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"6354_CR222","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-019-0716-4","volume":"7","author":"JH Lee","year":"2019","unstructured":"Lee JH, Han J-H, Kim H, Park SM, Joe E-H, Jou I. Parkinson\u2019s disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes. Acta Neuropathol Commun. 2019;7(1):1\u201319.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"6354_CR223","doi-asserted-by":"publisher","first-page":"e135633","DOI":"10.1172\/jci.insight.135633","volume":"6","author":"TA Cole","year":"2021","unstructured":"Cole TA, Zhao H, Collier TJ, Sandoval I, Sortwell CE, Steece-Collier K, et al. \u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease. JCI insight. 2021;6(5):e135633.","journal-title":"JCI insight."},{"issue":"2","key":"6354_CR224","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7555\/JBR.33.20190090","volume":"34","author":"K Yan","year":"2020","unstructured":"Yan K, Zhang W, Han X, Chang F, Liu Y. Inhibitory role of peroxiredoxin 2 in LRRK2 kinase activity induced cellular pathogenesis. J Biomed Res. 2020;34(2):103.","journal-title":"J Biomed Res"},{"key":"6354_CR225","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.nbd.2016.11.004","volume":"98","author":"X Ding","year":"2017","unstructured":"Ding X, Barodia SK, Ma L, Goldberg MS. Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity. Neurobiol Dis. 2017;98:122\u201336.","journal-title":"Neurobiol Dis"},{"key":"6354_CR226","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.17.613365","author":"ND Raig","year":"2024","unstructured":"Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Kramer A, Schwalm MP, et al. Type-II kinase inhibitors that target Parkinson\u2019s disease-associated LRRK2. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.09.17.613365.","journal-title":"bioRxiv."},{"issue":"6_Supplement","key":"6354_CR227","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1538-7445.AM2024-3298","volume":"84","author":"ME Riveiro","year":"2024","unstructured":"Riveiro ME, Blom P, Shoji K, Hoflack J. Unlocking the potential of OPM-383: a novel LRRK2 inhibitor in cancer therapy. Cancer Res. 2024;84(6_Supplement):3298.","journal-title":"Cancer Res"},{"issue":"3","key":"6354_CR228","doi-asserted-by":"publisher","first-page":"319","DOI":"10.15283\/ijsc24032","volume":"17","author":"S Park","year":"2024","unstructured":"Park S, Kim K-H, Bae Y-H, Oh YT, Shin H, Kwon HJ, et al. Suppression of glioblastoma stem cell potency and tumor growth via LRRK2 inhibition. Int J Stem Cells. 2024;17(3):319\u201329.","journal-title":"Int J Stem Cells"},{"issue":"3","key":"6354_CR229","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00109-020-01878-y","volume":"98","author":"JM Ogier","year":"2020","unstructured":"Ogier JM, Nayagam BA, Lockhart PJ. ASK1 inhibition: a therapeutic strategy with multi-system benefits. J Mol Med. 2020;98(3):335\u201348.","journal-title":"J Mol Med"},{"issue":"4","key":"6354_CR230","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1139\/bcb-2017-0262","volume":"96","author":"D Yang","year":"2018","unstructured":"Yang D, Thomas JM, Li T, Lee Y, Liu Z, Smith WW. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration. Biochem Cell Biol. 2018;96(4):441\u20139.","journal-title":"Biochem Cell Biol"},{"issue":"1","key":"6354_CR231","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40035-024-00403-2","volume":"13","author":"N Lubben","year":"2024","unstructured":"Lubben N, Brynildsen JK, Webb CM, Li HL, Leyns CE, Changolkar L, et al. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression. Transl Neurodegener. 2024;13(1):13.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"6354_CR232","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13064-024-00193-3","volume":"19","author":"G Holmes","year":"2024","unstructured":"Holmes G, Ferguson SR, Lewis PA, Echeverri K. LRRK2 kinase activity is necessary for development and regeneration in Nematostella vectensis. Neural Dev. 2024;19(1):16.","journal-title":"Neural Dev"},{"issue":"1","key":"6354_CR233","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14552","volume":"30","author":"R Ben\u00edtez-Fern\u00e1ndez","year":"2024","unstructured":"Ben\u00edtez-Fern\u00e1ndez R, Josa-Prado F, S\u00e1nchez E, Lao Y, Garc\u00eda-Rubia A, Cumella J, et al. Efficacy of a benzothiazole-based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis. CNS Neurosci Ther. 2024;30(1): e14552.","journal-title":"CNS Neurosci Ther"},{"key":"6354_CR234","first-page":"177","volume":"8","author":"F Atashrazm","year":"2016","unstructured":"Atashrazm F, Dzamko N. LRRK2 inhibitors and their potential in the treatment of Parkinson\u2019s disease: current perspectives. Clin Pharmacol. 2016;8:177.","journal-title":"Clin Pharmacol"},{"key":"6354_CR235","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tox.2018.01.003","volume":"395","author":"MA Andersen","year":"2018","unstructured":"Andersen MA, Wegener KM, Larsen S, Badolo L, Smith GP, Jeggo R, et al. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology. 2018;395:15\u201322.","journal-title":"Toxicology"},{"issue":"3","key":"6354_CR236","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"MJ Fell","year":"2015","unstructured":"Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, et al. MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther. 2015;355(3):397\u2013409.","journal-title":"J Pharmacol Exp Ther"},{"issue":"273","key":"6354_CR237","doi-asserted-by":"publisher","first-page":"273ra15","DOI":"10.1126\/scitranslmed.aaa3634","volume":"7","author":"RN Fuji","year":"2015","unstructured":"Fuji RN, Flagella M, Baca M, Baptista MAS, Brodbeck J, Chan BK, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med. 2015;7(273):273ra15.","journal-title":"Sci Transl Med"},{"issue":"540","key":"6354_CR238","doi-asserted-by":"publisher","first-page":"eaav0820","DOI":"10.1126\/scitranslmed.aav0820","volume":"12","author":"MA Baptista","year":"2020","unstructured":"Baptista MA, Merchant K, Barrett T, Bryce DK, Ellis M, Estrada AA, et al. LRRK2 kinase inhibitors induce a reversible effect in the lungs of non-human primates with no measurable pulmonary deficits. Sci Transl Med. 2020;12(540):eaav0820.","journal-title":"Sci Transl Med."},{"issue":"LRRK2","key":"6354_CR239","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-3-319-49969-7_7","volume":"2","author":"NL Dzamko","year":"2017","unstructured":"Dzamko NL. LRRK2 and the immune system. Leucine-Rich Repeat Kinase. 2017;2(LRRK2):123\u201343.","journal-title":"Leucine-Rich Repeat Kinase"},{"issue":"11","key":"6354_CR240","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165949","volume":"11","author":"A Speidel","year":"2016","unstructured":"Speidel A, Felk S, Reinhardt P, Sterneckert J, Gillardon F. Leucine-rich repeat kinase 2 influences fate decision of human monocytes differentiated from induced pluripotent stem cells. PLoS ONE. 2016;11(11): e0165949.","journal-title":"PLoS ONE"},{"issue":"16","key":"6354_CR241","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1093\/hmg\/ddu138","volume":"23","author":"J Schapansky","year":"2014","unstructured":"Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet. 2014;23(16):4201\u201314.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"6354_CR242","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1084\/jem.20170014","volume":"214","author":"W Liu","year":"2017","unstructured":"Liu W, Xn L, Li Y, Zhao J, Liu Z, Hu Z, et al. LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection. J Exp Med. 2017;214(10):3051\u201366.","journal-title":"J Exp Med"},{"issue":"6","key":"6354_CR243","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/brain\/awy077","volume":"141","author":"E Kozina","year":"2018","unstructured":"Kozina E, Sadasivan S, Jiao Y, Dou Y, Ma Z, Tan H, et al. Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. Brain. 2018;141(6):1753\u201369.","journal-title":"Brain"},{"issue":"4","key":"6354_CR244","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"E Pais\u00e1n-Rui\u0301z","year":"2004","unstructured":"Pais\u00e1n-Rui\u0301z E, Jain S, Evans EW, Gilks WP, Sim\u00f3n WP, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron. 2004;44(4):595\u2013600.","journal-title":"Neuron"},{"key":"6354_CR245","first-page":"177","volume":"8","author":"F Atashrazm","year":"2016","unstructured":"Atashrazm F, Dzamko N. LRRK2 inhibitors and their potential in the treatment of Parkinson\u2019s disease: current perspectives. Clin Pharmacol. 2016;8:177\u201389.","journal-title":"Clin Pharmacol"},{"issue":"1","key":"6354_CR246","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022;7(1):113.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"6354_CR247","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cmdc.202000872","volume":"16","author":"M Konstantinidou","year":"2021","unstructured":"Konstantinidou M, Oun A, Pathak P, Zhang B, Wang Z, ter Brake F, et al. The tale of proteolysis targeting chimeras (PROTACs) for leucine-rich repeat kinase 2 (LRRK2). ChemMedChem. 2021;16(6):959\u201365.","journal-title":"ChemMedChem"},{"issue":"15","key":"6354_CR248","doi-asserted-by":"publisher","first-page":"10183","DOI":"10.1021\/acs.jmedchem.2c00691","volume":"65","author":"Y Li","year":"2022","unstructured":"Li Y, Song J, Zhou P, Zhou J, Xie S. Targeting undruggable transcription factors with PROTACs: advances and perspectives. J Med Chem. 2022;65(15):10183\u201394.","journal-title":"J Med Chem"},{"issue":"1","key":"6354_CR249","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","volume":"7","author":"M He","year":"2022","unstructured":"He M, Cao C, Ni Z, Liu Y, Song P, Hao S, et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther. 2022;7(1):181.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"6354_CR250","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001;98(15):8554\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6354_CR251","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","volume":"16","author":"Z Li","year":"2020","unstructured":"Li Z, Zhu C, Ding Y, Fei Y, Lu B. ATTEC: a potential new approach to target proteinopathies. Autophagy. 2020;16(1):185\u20137.","journal-title":"Autophagy"},{"issue":"1","key":"6354_CR252","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","volume":"13","author":"CH Ji","year":"2022","unstructured":"Ji CH, Kim HY, Lee MJ, Heo AJ, Park DY, Lim S, et al. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. Nat Commun. 2022;13(1):904.","journal-title":"Nat Commun"},{"issue":"11","key":"6354_CR253","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1021\/acsmedchemlett.0c00453","volume":"11","author":"RB Kargbo","year":"2020","unstructured":"Kargbo RB. Degradation of LRRK2 in the treatment of Parkinson\u2019s disease. ACS Med Chem Lett. 2020;11(11):2070\u20131.","journal-title":"ACS Med Chem Lett"},{"issue":"37","key":"6354_CR254","doi-asserted-by":"publisher","first-page":"16930","DOI":"10.1021\/jacs.2c05499","volume":"144","author":"X Liu","year":"2022","unstructured":"Liu X, Kalogeropulou AF, Domingos S, Makukhin N, Nirujogi RS, Singh F, et al. Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2. J Am Chem Soc. 2022;144(37):16930\u201352.","journal-title":"J Am Chem Soc"},{"key":"6354_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129449","volume":"94","author":"JM Hatcher","year":"2023","unstructured":"Hatcher JM, Zwirek M, Sarhan AR, Vatsan PS, Tonelli F, Alessi DR, et al. Development of a highly potent and selective degrader of LRRK2. Bioorg Med Chem Lett. 2023;94: 129449.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"6354_CR256","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","volume":"9","author":"J-M Taymans","year":"2023","unstructured":"Taymans J-M, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, et al. Perspective on the current state of the LRRK2 field. NPJ Parkinson\u2019s Dis. 2023;9(1):104.","journal-title":"NPJ Parkinson's Dis"},{"issue":"4","key":"6354_CR257","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/ane.13700","volume":"146","author":"HR Morris","year":"2022","unstructured":"Morris HR. Blood based biomarkers for movement disorders. Acta Neurol Scand. 2022;146(4):353\u201361.","journal-title":"Acta Neurol Scand"},{"issue":"22","key":"6354_CR258","doi-asserted-by":"publisher","first-page":"12379","DOI":"10.3390\/ijms252212379","volume":"25","author":"R Arya","year":"2024","unstructured":"Arya R, Haque AKMA, Shakya H, Billah MM, Parvin A, Rahman M-M, et al. Parkinson\u2019s disease: biomarkers for diagnosis and disease progression. Int J Mol Sci. 2024;25(22):12379.","journal-title":"Int J Mol Sci"},{"key":"6354_CR259","doi-asserted-by":"publisher","first-page":"880914","DOI":"10.3389\/fnins.2022.880914","volume":"16","author":"H Rideout","year":"2022","unstructured":"Rideout H, Greggio E, Kortholt A, Nichols RJ. LRRK2\u2014fifteen years from cloning to the clinic. Front Neurosci. 2022;16:880914.","journal-title":"Front Neurosci"},{"issue":"1","key":"6354_CR260","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/BST20160334","volume":"45","author":"JM Taymans","year":"2017","unstructured":"Taymans JM, Mutez E, Drouyer M, Sibran W, Chartier-Harlin MC. LRRK2 detection in human biofluids: potential use as a Parkinson\u2019s disease biomarker? Biochem Soc Trans. 2017;45(1):207\u201312.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"6354_CR261","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-74195-6","volume":"10","author":"C Gonzalez-Hunt","year":"2020","unstructured":"Gonzalez-Hunt C, Thacker E, Toste C, Boularand S, Deprets S, Dubois L, et al. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson\u2019s disease. Sci Rep. 2020;10(1):1\u201312.","journal-title":"Sci Rep"},{"issue":"6","key":"6354_CR262","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.26529","volume":"31","author":"N Dzamko","year":"2016","unstructured":"Dzamko N, Rowe DB, Halliday GM. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. Mov Disord. 2016;31(6):889\u201397.","journal-title":"Mov Disord"},{"issue":"2","key":"6354_CR263","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/biom12020329","volume":"12","author":"EH Kwon","year":"2022","unstructured":"Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, T\u00f6nges L. Update on CSF biomarkers in Parkinson\u2019s disease. Biomolecules. 2022;12(2):329.","journal-title":"Biomolecules"},{"issue":"1","key":"6354_CR264","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40478-017-0492-y","volume":"5","author":"S Wang","year":"2017","unstructured":"Wang S, Liu Z, Ye T, Mabrouk OS, Maltbie T, Aasly J, et al. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathol Commun. 2017;5(1):86.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"6354_CR265","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/mds.26591","volume":"31","author":"D Vilas","year":"2016","unstructured":"Vilas D, Shaw LM, Taylor P, Berg D, Brockmann K, Aasly J, et al. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. Mov Disord. 2016;31(6):906\u201314.","journal-title":"Mov Disord"},{"issue":"24","key":"6354_CR266","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1093\/hmg\/ddt346","volume":"22","author":"KB Fraser","year":"2013","unstructured":"Fraser KB, Moehle MS, Daher JP, Webber PJ, Williams JY, Stewart CA, et al. LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Genet. 2013;22(24):4988\u20135000.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"6354_CR267","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013257","volume":"13","author":"S Virreira Winter","year":"2021","unstructured":"Virreira Winter S, Karayel O, Strauss MT, Padmanabhan S, Surface M, Merchant K, et al. Urinary proteome profiling for stratifying patients with familial Parkinson\u2019s disease. EMBO Mol Med. 2021;13(3): e13257.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"6354_CR268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02047-y","volume":"21","author":"C Yang","year":"2021","unstructured":"Yang C, Pang J, Xu J, Pan H, Li Y, Zhang H, et al. LRRK2 is a candidate prognostic biomarker for clear cell renal cell carcinoma. Cancer Cell Int. 2021;21(1):1\u201320.","journal-title":"Cancer Cell Int"},{"key":"6354_CR269","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fnins.2020.00526","volume":"14","author":"OS Mabrouk","year":"2020","unstructured":"Mabrouk OS, Chen S, Edwards AL, Yang M, Hirst WD, Graham DL. Quantitative measurements of LRRK2 in human cerebrospinal fluid demonstrates increased levels in G2019S patients. Front Neurosci. 2020;14:526.","journal-title":"Front Neurosci"},{"issue":"5","key":"6354_CR270","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/mds.28927","volume":"37","author":"A Garrido","year":"2022","unstructured":"Garrido A, Santamar\u00eda E, Fern\u00e1ndez-Irigoyen J, Soto M, Simonet C, Fern\u00e1ndez M, et al. Differential phospho-signatures in blood cells identify LRRK2 G2019S carriers in Parkinson\u2019s disease. Mov Disord. 2022;37(5):1004\u201315.","journal-title":"Mov Disord"},{"issue":"5","key":"6354_CR271","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ana.26469","volume":"92","author":"A Garrido","year":"2022","unstructured":"Garrido A, P\u00e9rez-Sisqu\u00e9s L, Simonet C, Campoy-Campos G, Solana-Balaguer J, Mart\u00edn-Flores N, et al. Increased phospho-AKT in blood cells from LRRK2 G2019S mutation carriers. Ann Neurol. 2022;92(5):888\u201394.","journal-title":"Ann Neurol"},{"issue":"3","key":"6354_CR272","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00401-021-02325-z","volume":"142","author":"Y Fan","year":"2021","unstructured":"Fan Y, Nirujogi RS, Garrido A, Ruiz-Mart\u00ednez J, Bergareche-Yarza A, Mondrag\u00f3n-Rezola E, et al. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathol. 2021;142(3):475\u201394.","journal-title":"Acta Neuropathol"},{"issue":"34","key":"6354_CR273","doi-asserted-by":"publisher","first-page":"54215","DOI":"10.18632\/oncotarget.11090","volume":"7","author":"C-C Chiu","year":"2016","unstructured":"Chiu C-C, Yeh T-H, Lai S-C, Weng Y-H, Huang Y-C, Cheng Y-C, et al. Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson\u2019s disease. Oncotarget. 2016;7(34):54215.","journal-title":"Oncotarget"},{"key":"6354_CR274","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jpba.2012.12.002","volume":"76","author":"L Delbroek","year":"2013","unstructured":"Delbroek L, Van Kolen K, Steegmans L, da Cunha R, Mandemakers W, Daneels G, et al. Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation. J Pharm Biomed Anal. 2013;76:49\u201358.","journal-title":"J Pharm Biomed Anal"},{"key":"6354_CR275","doi-asserted-by":"publisher","first-page":"31391","DOI":"10.1038\/srep31391","volume":"6","author":"G Perera","year":"2016","unstructured":"Perera G, Ranola M, Rowe DB, Halliday GM, Dzamko N. Inhibitor treatment of peripheral mononuclear cells from Parkinson\u2019s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Sci Rep. 2016;6:31391.","journal-title":"Sci Rep"},{"issue":"1","key":"6354_CR276","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41531-022-00354-3","volume":"8","author":"M Kedariti","year":"2022","unstructured":"Kedariti M, Frattini E, Baden P, Cogo S, Civiero L, Ziviani E, et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):92.","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"6354_CR277","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/mds.28175","volume":"35","author":"K Melachroinou","year":"2020","unstructured":"Melachroinou K, Kang MS, Liong C, Narayan S, Levers N, Joshi N, et al. Elevated in vitro kinase activity in peripheral blood mononuclear cells of leucine-rich repeat kinase 2 G2019S carriers: a novel enzyme-linked immunosorbent assay-based method. Mov Disord. 2020;35(11):2095\u2013100.","journal-title":"Mov Disord"},{"issue":"9","key":"6354_CR278","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1074\/mcp.RA120.002055","volume":"19","author":"\u00d6 Karayel","year":"2020","unstructured":"Karayel \u00d6, Tonelli F, Virreira Winter S, Geyer PE, Fan Y, Sammler EM, et al. Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 activity in Parkinson\u2019s disease. Mol Cell Proteomics. 2020;19(9):1546\u201360.","journal-title":"Mol Cell Proteomics"},{"issue":"17","key":"6354_CR279","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/cmdc.201900321","volume":"14","author":"Z Chen","year":"2019","unstructured":"Chen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, et al. Synthesis and preliminary evaluation of [(11) C]GNE-1023 as a potent PET probe for imaging leucine-rich repeat kinase 2 (LRRK2) in Parkinson\u2019s disease. ChemMedChem. 2019;14(17):1580\u20135.","journal-title":"ChemMedChem"},{"issue":"1","key":"6354_CR280","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1042\/BCJ20170870","volume":"475","author":"PA Eyers","year":"2018","unstructured":"Eyers PA. Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson\u2019s disease. Biochem J. 2018;475(1):185\u20139.","journal-title":"Biochem J"},{"issue":"2","key":"6354_CR281","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3233\/JPD-191786","volume":"10","author":"S Padmanabhan","year":"2020","unstructured":"Padmanabhan S, Lanz TA, Gorman D, Wolfe M, Joyce A, Cabrera C, et al. An assessment of LRRK2 serine 935 phosphorylation in human peripheral blood mononuclear cells in idiopathic Parkinson\u2019s disease and G2019S LRRK2 cohorts. J Parkinsons Dis. 2020;10(2):623\u20139.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"6354_CR282","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1681\/ASN.2008040406","volume":"20","author":"PA Gonzales","year":"2009","unstructured":"Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 2009;20(2):363\u201379.","journal-title":"J Am Soc Nephrol"},{"key":"6354_CR283","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113005","volume":"211","author":"N Malik","year":"2021","unstructured":"Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, et al. Development and biological evaluation of[(18)F]FMN3PA & [(18)F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging. Eur J Med Chem. 2021;211: 113005.","journal-title":"Eur J Med Chem"},{"key":"6354_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113245","volume":"214","author":"X Chen","year":"2021","unstructured":"Chen X, Zhang Q, Zhang Y, Fang J, Jiang D, Mou Z, et al. (18)F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson\u2019s disease. Eur J Med Chem. 2021;214: 113245.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"6354_CR285","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.bmcl.2017.02.019","volume":"27","author":"M Wang","year":"2017","unstructured":"Wang M, Gao M, Xu Z, Zheng QH. Synthesis of [(11)C]HG-10-102-01 as a new potential PET agent for imaging of LRRK2 enzyme in Parkinson\u2019s disease. Bioorg Med Chem Lett. 2017;27(6):1351\u20135.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"6354_CR286","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16(2):97\u2013107.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"6354_CR287","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbrc.2008.11.048","volume":"378","author":"JP Covy","year":"2009","unstructured":"Covy JP, Giasson BI. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun. 2009;378(3):473\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"6354_CR288","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/hmg\/dds431","volume":"22","author":"C Yao","year":"2013","unstructured":"Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, et al. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet. 2013;22(2):328\u201344.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"6354_CR289","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/neurolint12030017","volume":"12","author":"AA Berger","year":"2020","unstructured":"Berger AA, Winnick A, Welschmeyer A, Kaneb A, Berardino K, Cornett EM, et al. Istradefylline to treat patients with Parkinson\u2019s disease experiencing \u201coff\u201d episodes: A comprehensive review. Neurol Int. 2020;12(3):109\u201329.","journal-title":"Neurol Int"},{"issue":"12","key":"6354_CR290","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00018-022-04574-x","volume":"79","author":"ZD Zhou","year":"2022","unstructured":"Zhou ZD, Saw WT, Ho PGH, Zhang ZW, Zeng L, Chang YY, et al. The role of tyrosine hydroxylase\u2013dopamine pathway in Parkinson\u2019s disease pathogenesis. Cell Mol Life Sci. 2022;79(12):1\u201321.","journal-title":"Cell Mol Life Sci"},{"key":"6354_CR291","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.12.001","volume":"36","author":"M Mohan","year":"2017","unstructured":"Mohan M, Mellick GD. Role of the VPS35 D620N mutation in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2017;36:10\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"35","key":"6354_CR292","doi-asserted-by":"publisher","first-page":"18283","DOI":"10.1074\/jbc.M115.703157","volume":"291","author":"J Follett","year":"2016","unstructured":"Follett J, Bugarcic A, Yang Z, Ariotti N, Norwood SJ, Collins BM, et al. Parkinson disease-linked Vps35 R524W mutation impairs the endosomal association of retromer and induces \u03b1-synuclein aggregation. J Biol Chem. 2016;291(35):18283\u201398.","journal-title":"J Biol Chem"},{"issue":"1","key":"6354_CR293","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-022-00281-6","volume":"11","author":"SY-Y Pang","year":"2022","unstructured":"Pang SY-Y, Lo RCN, Ho PW-L, Liu H-F, Chang EES, Leung C-T, et al. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson\u2019s disease. Transl Neurodegener. 2022;11(1):1\u201314.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"6354_CR294","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1021\/acsmedchemlett.1c00687","volume":"13","author":"RW Sabnis","year":"2022","unstructured":"Sabnis RW. Novel macrocyclic LRRK2 inhibitors for treating Parkinson\u2019s disease. ACS Med Chem Lett. 2022;13(1):25\u20136.","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"6354_CR295","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/ml300123a","volume":"3","author":"HG Choi","year":"2012","unstructured":"Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, et al. Brain penetrant LRRK2 inhibitor. ACS Med Chem Lett. 2012;3(8):658\u201362.","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"6354_CR296","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/cddis.2014.320","volume":"5","author":"S Saez-Atienzar","year":"2014","unstructured":"Saez-Atienzar S, Bonet-Ponce L, Blesa JR, Romero FJ, Murphy MP, Jordan J, et al. The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis. 2014;5(8):1368.","journal-title":"Cell Death Dis"},{"issue":"23","key":"6354_CR297","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2100844118","volume":"118","author":"SH Schmidt","year":"2021","unstructured":"Schmidt SH, Weng J-H, Aoto PC, Boassa D, Mathea S, Silletti S, et al. Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2. Proc Natl Acad Sci. 2021;118(23): e2100844118.","journal-title":"Proc Natl Acad Sci"},{"issue":"648","key":"6354_CR298","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med. 2022;14(648):2658.","journal-title":"Sci Transl Med"},{"issue":"3","key":"6354_CR299","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.stem.2013.01.008","volume":"12","author":"P Reinhardt","year":"2013","unstructured":"Reinhardt P, Schmid B, Burbulla Lena F, Sch\u00f6ndorf David C, Wagner L, Glatza M, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12(3):354\u201367.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"6354_CR300","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-60273-2","volume":"10","author":"SC Vermilyea","year":"2020","unstructured":"Vermilyea SC, Babinski A, Tran N, To S, Guthrie S, Kluss JH, et al. In vitro CRISPR\/Cas9-directed gene editing to model LRRK2 G2019S Parkinson\u2019s disease in common marmosets. Sci Rep. 2020;10(1):1\u201315.","journal-title":"Sci Rep"},{"key":"6354_CR301","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2020.102073","volume":"49","author":"E Ohta","year":"2020","unstructured":"Ohta E, Sone T, Ukai H, Hisamatsu T, Kitagawa T, Ishikawa M, et al. Generation of gene-corrected iPSCs line (KEIUi001-A) from a PARK8 patient iPSCs with familial Parkinson\u2019s disease carrying the I2020T mutation in LRRK2. Stem Cell Res. 2020;49: 102073.","journal-title":"Stem Cell Res"},{"key":"6354_CR302","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2019.101649","volume":"41","author":"SY Lee","year":"2019","unstructured":"Lee SY, Chung SK. Generation of gene-corrected iPSC line, KIOMi002-A, from Parkinson\u2019s disease patient iPSC with LRRK2 G2019S mutation using BAC-based homologous recombination. Stem Cell Res. 2019;41: 101649.","journal-title":"Stem Cell Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06354-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06354-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06354-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:30:00Z","timestamp":1752139800000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06354-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":302,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6354"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06354-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"754"}}